IL6 and metabolic dysfunction-associated steatotic liver disease: Furthermore, the administration of rifaximin for 4–12 weeks has been shown to decrease the blood levels of IL-6, IL-10, and TNF-α in patients with nonalcoholic fatty liver disease and cirrhosis with HE [47,48,49].